Qianyuan Pharmaceutical announced that the company plans to apply for two merger and acquisition loans from the Weidu branch of the Datong branch of the Industrial and Commercial Bank of China, totaling no more than 152 million yuan, and the loan period of no more than 7 years to replace the portion of the completed transfer of 34% of the shares in Nantong Hengjia and 20% of Qianyuan Hailisheng's shares exceeding equity capital. The company plans to pledge 80% of Qianyuan Hailisheng's shares and 87% of Jiangsu Jiayi's shares. The subsidiaries Qianyuan Hailisheng, Qianyuan Boring and related parties Huang Lequn and Zhao Qun will provide joint liability guarantees, while providing second-line collateral with land and real estate related to Qianyuan Hailisheng. There is no need to submit this matter to the shareholders' meeting for consideration, and the final terms are subject to a duly signed document.

Qianyuan Pharmaceutical announced that the company plans to apply for two merger and acquisition loans from the Weidu branch of the Datong branch of the Industrial and Commercial Bank of China, totaling no more than 152 million yuan, and the loan period of no more than 7 years to replace the portion of the completed transfer of 34% of the shares in Nantong Hengjia and 20% of Qianyuan Hailisheng's shares exceeding equity capital. The company plans to pledge 80% of Qianyuan Hailisheng's shares and 87% of Jiangsu Jiayi's shares. The subsidiaries Qianyuan Hailisheng, Qianyuan Boring and related parties Huang Lequn and Zhao Qun will provide joint liability guarantees, while providing second-line collateral with land and real estate related to Qianyuan Hailisheng. There is no need to submit this matter to the shareholders' meeting for consideration, and the final terms are subject to a duly signed document.